Renal Transplant Clinical Trial
Official title:
A Randomized, Open, Controlled Trial of High Dose IVIG/Rituximab Versus Rituximab in Kidney Transplant Patients With de Novo Donor-specific Antibodies
The objective of this study was to compare two strategies of de novo donor specific antibodies (DSA) and antibody-mediated rejection (AMR) prevention in renal transplant recipients: high dose intravenous immunoglobulin (IVIG)/rituximab regimens versus rituximab alone.
Although recent advances in immunosuppressive regimens after kidney transplantation (KT) have reduced the incidence and consequences of T-cell-mediated rejection (TCMR) and have improved short-term outcomes, long-term allograft loss attributable to AMR is still responsible for substantial medical and socioeconomic burdens in kidney transplant recipients. Numerous studies have shown that de novo DSA after KT are associated with AMR, which leads to allograft loss. IVIG is a medication that has emerged as a useful tool in modulating immunity, treatment of AMR and in desensitization protocol. Treatment with rituximab or combination of IVIG/rituximab has sought to further diminish antibody production (de novo DSA) in the treatment of AMR. Several studies have been reported, but in the absence of control groups or standardization of treatment, their efficacy is difficult to assess. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01220050 -
Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism
|
Phase 2 | |
Completed |
NCT00820469 -
Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab
|
Phase 4 | |
Completed |
NCT00239005 -
Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation
|
Phase 4 | |
Completed |
NCT00270153 -
The Use of ACE Inhibitors in the Early Renal Post-transplant Period
|
Phase 1 | |
Completed |
NCT02711826 -
Treg Therapy in Subclinical Inflammation in Kidney Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT03837522 -
Trial to Define the Benefits and Harms of Deceased Donor Kidney Procurement Biopsies
|
N/A | |
Not yet recruiting |
NCT06025240 -
Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
|
||
Completed |
NCT01256294 -
Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients
|
Phase 4 | |
Suspended |
NCT01059292 -
TIPE2 Associated With Kidney Transplant
|
N/A | |
Completed |
NCT00547040 -
Arterial Stiffness and Calcifications in Incident Renal Transplant Recipients
|
||
Suspended |
NCT03043339 -
Characterization Of the Intestinal Microbiome Evolution After Kidney Transplant Donation or Receipt
|
||
Completed |
NCT02581644 -
Assessment of Effectiveness of Belatacept Patient Alert Card in Patients Following Renal Transplantation in a Sample of EU Countries
|
N/A | |
Completed |
NCT01728012 -
Long-term Cardiovascular Risk Following Successful Renal Transplantation
|
N/A | |
Terminated |
NCT01011114 -
Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant
|
N/A | |
Completed |
NCT00555373 -
Pediatric Kidney Transplant Study of Sirolimus, Mycophenolate Mofetil, and Corticosteroids vs Calcineurin Inhibitor Based Immunosuppression
|
N/A | |
Completed |
NCT02117596 -
Calcineurin Inhibitor Based Immunosuppression Withdrawal
|
N/A | |
Recruiting |
NCT05156086 -
Safety and Effectiveness of COVID-19 Vaccine in Kidney Transplant Recipients
|
||
Completed |
NCT01334333 -
Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients
|
Phase 4 | |
Recruiting |
NCT03107858 -
The Effect of Norepinephrine Versus Dopamine in Renal Transplant Recipients on Postoperative Graft Function
|
Phase 2/Phase 3 | |
Completed |
NCT00352547 -
Influence of Genes on Sirolimus Metabolism in Patients With Kidney Transplantation
|
N/A |